Transgene Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

TransgeneDer Gewinn des Unternehmens wird voraussichtlich um 34.8% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 2.9% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-34.8%

Wachstumsrate der Gewinne

-35.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	4.6%
Wachstumsrate der Einnahmen	2.9%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	14 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Recent updates

Is Transgene (EPA:TNG) Using Too Much Debt?

Jun 15

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Mar 21

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mar 19

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Jan 23

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:TNG - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	12	-56	-62	-61	1
12/31/2025	17	-47	-54	-52	1
12/31/2024	22	-30	-40	-38	1
6/30/2024	6	-23	-39	-36	N/A
3/31/2024	7	-23	-38	-35	N/A
12/31/2023	8	-22	-37	-35	N/A
9/30/2023	8	-28	-36	-34	N/A
6/30/2023	9	-33	-35	-33	N/A
3/31/2023	10	-33	-28	-26	N/A
12/31/2022	10	-33	-22	-20	N/A
9/30/2022	14	-28	-18	-17	N/A
6/30/2022	18	-23	-15	-15	N/A
3/31/2022	18	-21	-21	-20	N/A
12/31/2021	17	-20	-27	-26	N/A
9/30/2021	13	-23	-29	-28	N/A
6/30/2021	9	-27	-31	-30	N/A
3/31/2021	9	-22	-30	-29	N/A
12/31/2020	10	-17	-30	-29	N/A
9/30/2020	12	-11	-31	-30	N/A
6/30/2020	14	-6	-33	-31	N/A
3/31/2020	14	-12	-28	-27	N/A
12/31/2019	13	-19	-24	-22	N/A
9/30/2019	11	-6	-24	-23	N/A
6/30/2019	8	8	-23	-23	N/A
3/31/2019	8	8	-26	-25	N/A
12/31/2018	7	8	-29	-28	N/A
9/30/2018	7	-10	-31	-29	N/A
6/30/2018	7	-29	-32	-30	N/A
3/31/2018	7	-31	N/A	-33	N/A
12/31/2017	7	-32	N/A	-35	N/A
9/30/2017	8	-32	N/A	-36	N/A
6/30/2017	9	-31	N/A	-37	N/A
3/31/2017	9	-28	N/A	-35	N/A
12/31/2016	10	-24	N/A	-34	N/A
9/30/2016	10	-26	N/A	-37	N/A
6/30/2016	9	-28	N/A	-40	N/A
3/31/2016	9	-33	N/A	-43	N/A
12/31/2015	10	-38	N/A	-45	N/A
9/30/2015	10	-40	N/A	-48	N/A
6/30/2015	10	-42	N/A	-50	N/A
3/31/2015	11	-41	N/A	-52	N/A
12/31/2014	11	-41	N/A	-54	N/A
9/30/2014	13	-41	N/A	-52	N/A
6/30/2014	15	-41	N/A	-50	N/A
3/31/2014	15	-42	N/A	-50	N/A
12/31/2013	16	-43	N/A	-50	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: TNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: TNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: TNG wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: TNGDie Einnahmen des Unternehmens (2.9% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (5.6% pro Jahr).

Hohe Wachstumseinnahmen: TNGDie Einnahmen des Unternehmens (2.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von TNG in 3 Jahren voraussichtlich hoch sein wird

Transgene Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 45%

Price target decreased by 11% to €3.50

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

Consensus revenue estimates fall by 15%

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

First half 2024 earnings released: €0.16 loss per share (vs €0.16 loss in 1H 2023)

Bioinvent and Transgene’S Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase 1/2A Trial in Solid Tumors That Failed Previous Treatments

New minor risk - Shareholder dilution

Less than half of directors are independent

Consensus revenue estimates fall by 45%

Is Transgene (EPA:TNG) Using Too Much Debt?

New major risk - Financial position

New minor risk - Share price stability

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Transgene SA Announces Chief Financial Officer Changes

Transgene SA to Report Q3, 2024 Results on Nov 07, 2024

First half 2023 earnings released: €0.16 loss per share (vs €0.15 loss in 1H 2022)

First half 2023 earnings released

Price target decreased by 11% to €3.50

New major risk - Financial position

Consensus revenue estimates fall by 23%

Price target decreased by 7.6% to €3.67

BioInvent Ready for Combination Studies with BT-001

Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023

Transgene SA Presents Immunological Data Demonstrating TG4001, a Novel Therapeutic Cancer Vaccine, Can Induce T-cell Responses Against HPV16 Antigens in the Ongoing Phase II Trial at ASCO 2023

Transgene SA Appoints Carol Stuckley as Independent Director

Consensus revenue estimates fall by 15%

Downgrade: Here's How Analysts See Transgene SA (EPA:TNG) Performing In The Near Term

Transgene SA (EPA:TNG) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Transgene Receives Approval to Start a Phase I Trial of TG6050

Transgene SA to Report First Half, 2023 Results on Sep 20, 2023

No longer forecast to breakeven

Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab Vs Avelumab in HPV-Positive Anogenital Cancers

Transgene Confirms the Potential of the Intravenous Route of its Invir.IO Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022

First half 2022 earnings released: EPS: €0 (vs €0.14 loss in 1H 2021)

Transgene SA and BioInvent International AB (publ) Announce Positive Progress for BT-001

Transgene SA Presented Additional Phase I Data with TG4050 at ASCO 2022

Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® Platform) At Asco 2022

Transgene SA Approves Board and Committee Changes

No longer forecast to breakeven

Transgene’S Board of Directors Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman

Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?

No longer forecast to breakeven

Transgene to Present New Positive Preliminary Phase I Data on TG4050

Transgene SA Appoints Steven Bloom as Vice President and Chief Business Officer

Bioinvent International AB & Transgene Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD-1/ Anti-CTLA-4 Immune Checkpoint Blockade

Transgene (EPA:TNG) Has Debt But No Earnings; Should You Worry?

Transgene and NEC Corporation Announce Positive Preliminary Data from Phase I Studies of TG4050, A Novel Individualized Neoantigen Cancer Vaccine

First half 2021 earnings released

Transgene Announces Update on Phase I Clinical Trial of TG4050

Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg4001 + Avelumab Vs Avelumab Alone in Patients with HPV16-Positive Anogenital Cancers

Consensus forecasts updated

Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors

Bioinvent International AB and Transgene Receive IND Approval from the U.S. FDA for BT-001

Health Check: How Prudently Does Transgene (EPA:TNG) Use Debt?

Consensus forecasts updated

Transgene SA Develops Individualized Immunotherapy Based on Multiple Advanced Genetic Engineering Technologies

What Type Of Shareholders Own The Most Number of Transgene SA (EPA:TNG) Shares?

Full year 2020 earnings released: €0.21 loss per share (vs €0.23 loss in FY 2019)

Revenue and earnings miss expectations

New 90-day high: €2.70

Transgene and BioInvent International AB Enroll First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Does Transgene's (EPA:TNG) Share Price Gain of 62% Match Its Business Performance?

Transgene SA Announces the First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac Platform), Transgene’s Innovative Individualized Immunotherapy

Transgene Sa and Bioinvent Receive Approval from Ansm to Proceed with Phase I/Iia Trial of Anti-Ctla4-Armed Oncolytic Virus Bt-001 in Solid Tumors

Transgene Appoints Gaëlle Stadtler as Director of Human Resources

New 90-day high: €1.77

Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors

Transgene SA, Annual General Meeting, May 26, 2021

Transgene Announces Management Changes

New 90-day high: €1.75